SCHEMBL16626641

SCHEMBL16626641

CNCc1cn(S(=O)(=O)c2cccnc2)c2cc(Oc3cc(Cl)ccc3[N+](=O)[O-])ccc12

nearest known ligand 0.38

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.38
HTR6 P50406 4/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37
SLC6A4 P31645 10/20 0.36
HTR2A P28223 8/20 0.36
KCNH2 Q12809 8/20 0.36
BCL2 P10415 2/20 0.36
MCL1 Q07820 2/20 0.36
SLC6A2 P23975 2/20 0.35
TDP1 Q9NUW8 1/20 0.35
BCL2L1 Q07817 1/20 0.35
HTT P42858 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL16618961 0.99 POLB (0.38) POLBHTR6GAAMAPTSLC6A4
SCHEMBL16626787 0.91 HTR6 (0.40) HTR6GAAMAPTHTTSMN1; SMN2
Hydrochloric Acid SCHEMBL16618771 0.90 HTR6 (0.39) HTR6GAAMAPTHTTSMN1; SMN2
SCHEMBL19971347 0.88 POLB (0.37) POLBHTR6GAAMAPTBCL2
SCHEMBL16619016 0.86 HTR6 (0.39) POLBHTR6BCL2MCL1TDP1
SCHEMBL16619019 0.86 HTR6 (0.39) POLBHTR6BCL2MCL1TDP1
SCHEMBL19971450 0.84 POLB (0.36) POLBHTR6MAPTBCL2MCL1
SCHEMBL16626642 0.83 HTR6 (0.35) POLBHTR6BCL2MCL1TDP1
SCHEMBL17971584 0.82 PDE4A (0.41) HTR6SLC6A4HTR2AKCNH2SLC6A2
SCHEMBL16626656 0.80 SLC6A4 (0.46) HTR6SLC6A4HTR2AKCNH2SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3052484-B1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAE WOONG PHARMA (KR) 2018-03-21 EP claimed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
WO-2015050412-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME GIPR, PGC, SI POLB 4594/4885HTR6 166/4885GAA 738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.